Navigation Links
Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
Date:5/25/2010

NEW ORLEANS, May 25 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years.  The data, presented in an oral session at a national scientific meeting of psychiatrists in New Orleans, LA, demonstrated that treatment with Vyvanse (30, 50, and 70 mg/d) significantly improved ADHD symptoms compared to placebo in adolescents with ADHD.

Vyvanse is currently indicated for the treatment of ADHD in children aged 6 to 12 years and in adults.  Recently, Shire submitted a supplemental New Drug Application (sNDA) for use of Vyvanse in the treatment
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Discovery Laboratories, ... to advancing a new standard of respiratory critical ... on August 5, 2014 before the open of ... Company will host a live teleconference and webcast ... the conference call, Discovery Labs, management will discuss ...
(Date:7/29/2014)... 29, 2014  Cannabis Science, Inc. (OTC: CBIS), ... development and related consulting, applauds the Editorial Board ... strong position in opposition to current federal law ... publication.  The New York Times also announces a ... exploring the issue called "High Time:  An Editorial ...
(Date:7/29/2014)... & Rockville, MD (PRWEB) July 29, 2014 ... Inc. (ITI), a vaccine pioneer in the biotechnology ... services firm Newport Coast Securities, Inc. to explore ... is commercializing LAMP-vax technology, a breakthrough vaccine platform ... and immunotherapy market. The company exclusively licensed the ...
(Date:7/29/2014)... , July 29, 2014  Sigma-Aldrich Corporation (NASDAQ: ... and energy use, increased its investment in Green Chemistry ... around the world last year, the Company announced Monday ... if Science Changed the World? The ... several honors for being a responsible corporate citizen, including ...
Breaking Biology Technology:Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... , SAN MARINO, Calif., Aug. 7 ... a wholly owned subsidiary called MetaCytoLytics, Inc. This company was ... Professor M. Karen Newell called "metabolic disruption technology" (MDT), which ... from glucose or from fatty acids. That process has ...
... Aug. 6 AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported ... diluted, for the three months ended June 30, 2009, compared with ... diluted, for the three months ended June 30, 2008. For the ... or $0.02 per share basic and diluted, compared with net loss ...
... ROCKVILLE, Md., Aug. 6 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ... and commercialization of clinical-stage product candidates for central nervous system disorders, ... 30, 2009, on Monday, August 10, 2009, before the market opens. ... that time. , , Mihael H. Polymeropoulos, M.D., ...
Cached Biology Technology:Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4AutoImmune Inc. Reports 2009 Second Quarter Financial Results 2AutoImmune Inc. Reports 2009 Second Quarter Financial Results 3AutoImmune Inc. Reports 2009 Second Quarter Financial Results 4AutoImmune Inc. Reports 2009 Second Quarter Financial Results 5Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009 2
(Date:7/29/2014)... Achalasia is a rare disease it affects 1 in ... in the esophageal wall. While its cause remains unknown, a ... in Belgium, the University of Bonn in Germany and other ... autoimmune in origin. The study, published on 6 July in ... the mysterious disease. , When we swallow, a sphincter in ...
(Date:7/28/2014)... communities showing signs of damage from the Deepwater Horizon oil ... the Gulf of Mexico. The discovery was made by a ... State University. A paper describing this work and additional impacts ... will be published during the last week of July 2014 ... of the National Academy of Sciences . , "The footprint ...
(Date:7/28/2014)... Ariz. - Reactions among minerals and organic compounds in ... carbon cycle, they provide energy for the deep biosphere, ... However, very little is known about how minerals influence ... State University have demonstrated how a common mineral acts ... negating the need for toxic solvents or expensive reagents. ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3
... Two inventions created by University of Texas Medical Branch ... Texas Ignition Fund, a new program designed to spur ... One of the inventions, conceived by UTMB anesthesiology ... to deliver precise amounts of fluids to trauma and ...
... Beijing Genomics Institute announced today that BGI has added ... sequencing technologies. Two AB SOLiD Systems have been ... The AB SOLiD System generated high-throughput high quality mate-pair ... The highest throughput reached so far is 6.8 ...
... discovered that increasing age affects the way breast cancer behaves. ... likely to be diagnosed with aggressive tumours that have spread ... increasingly likely to spread, particularly if the tumours are small. ... and lymph node involvement and this study is the first ...
Cached Biology News:UTMB inventions win University of Texas System commercialization awards 2Breast cancers behave differently before and after the age of 70 2Breast cancers behave differently before and after the age of 70 3
... Avian Myeloblastosis Virus Reverse Transcriptase (AMV ... template DNA, RNA or RNA:DNA hybrids (1). ... more efficient than RNA primers) as well ... an intrinsic RNase H activity. Both nonionic ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... RQ1 RNase-Free DNase is a preparation ... or double-stranded DNA to produce 3-hydroxyl ... use in applications where maintaining the ... DNase is qualified for use with ...
... I, Wild Type Liquid. In 100 ... 200 µM EDTA, 20% glycerol, pH 7.9. AVOID ... is a monomeric protein of 765 amino acids ... relaxation of both positive and negative supercoiled DNAs ...
Biology Products: